engleski

Biologic immunotherapy in psoriasis

Psoriasis is generally considered as T cell mediated autoimmune disease. Recent studies in the pathogenesis of psoriasis has shown that upon triggering T lymphocytes secrete cytokines, chemokines and growth factors and consequently initiate keratinocyte proliferation. Besides traditionally immunomodulatory agents used in treatment of severe-to- moderate psoriasis such as photochemotherapy, methotrexate, cyclosporine and retinoids, new immunomodulatory therapy lately appeared. Those agents called biologic response modifiers or simply biologics act by targeting the precise elements in immunological cascade. Therefore, they can be classified into three categories: T-cell modulating agents (eg. alefacept and efalizumab), the inhibitors of tumor necrosis factor- alpha (TNF- alpha) (eg. adalimumab, etanercept, infliximab) and the inhibitors of interleukin (IL)-12 and IL-23 (eg. ustekinumab). Herein, we give a brief overwiev of action of those agents as well as present our experience in using these agents in therapy of psoriasis.

Psoriasis; Biologic immunotherapy; Infliximab; Adalimumab; Etanercept; Ustekinumab

nije evidentirano